These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

151 related articles for article (PubMed ID: 16014781)

  • 1. Invited commentary: how far can epidemiologists get with statistical adjustment?
    Petitti DB; Freedman DA
    Am J Epidemiol; 2005 Sep; 162(5):415-8; discussion 419-20. PubMed ID: 16014781
    [No Abstract]   [Full Text] [Related]  

  • 2. Re: "combined postmenopausal hormone therapy and cardiovascular disease: toward resolving the discrepancy between observational studies and the women's health initiative clinical trial".
    Willett WC; Manson JE; Grodstein F; Stampfer MJ; Colditz GA
    Am J Epidemiol; 2006 Jun; 163(11):1067-8; author reply 1068-9. PubMed ID: 16641306
    [No Abstract]   [Full Text] [Related]  

  • 3. Combined postmenopausal hormone therapy and cardiovascular disease: toward resolving the discrepancy between observational studies and the Women's Health Initiative clinical trial.
    Prentice RL; Langer R; Stefanick ML; Howard BV; Pettinger M; Anderson G; Barad D; Curb JD; Kotchen J; Kuller L; Limacher M; Wactawski-Wende J;
    Am J Epidemiol; 2005 Sep; 162(5):404-14. PubMed ID: 16033876
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Combined analysis of Women's Health Initiative observational and clinical trial data on postmenopausal hormone treatment and cardiovascular disease.
    Prentice RL; Langer RD; Stefanick ML; Howard BV; Pettinger M; Anderson GL; Barad D; Curb JD; Kotchen J; Kuller L; Limacher M; Wactawski-Wende J;
    Am J Epidemiol; 2006 Apr; 163(7):589-99. PubMed ID: 16484450
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Lung cancer and hormone replacement therapy.
    Canonico M; Plu-Bureau G; Scarabin PY
    Lancet; 2010 Jan; 375(9709):117; author reply 118-9. PubMed ID: 20109882
    [No Abstract]   [Full Text] [Related]  

  • 6. Abbreviated hormone replacement therapy trial answers some questions, raises new ones. The Women's Health Initiative is no longer testing the most widely prescribed estrogen and progestin combination--but the study's job is far from over.
    Harv Womens Health Watch; 2002 Oct; 10(2):2-4. PubMed ID: 12393317
    [No Abstract]   [Full Text] [Related]  

  • 7. Menopausal hormone therapy and risk for cardiovascular disease in the WHI trial.
    Pines A; Sturdee D
    Ann Intern Med; 2010 Jul; 153(1):61; author reply 61-2. PubMed ID: 20621912
    [No Abstract]   [Full Text] [Related]  

  • 8. Menopausal hormone therapy and risk for cardiovascular disease in the WHI trial.
    Sullivan JL
    Ann Intern Med; 2010 Jul; 153(1):61; author reply 61-2. PubMed ID: 20621911
    [No Abstract]   [Full Text] [Related]  

  • 9. Menopausal hormone therapy and risk for cardiovascular disease in the WHI trial.
    Harman SM; Brinton EA; Naftolin F; Merriam GR; Cedars MI; Freeman RG; Santoro N
    Ann Intern Med; 2010 Jul; 153(1):60-1; author reply 61-2. PubMed ID: 20621909
    [No Abstract]   [Full Text] [Related]  

  • 10. The Women's Health Initiative estrogen plus progestin trial: the study and how it changes our practice.
    Hendrix SL
    J Am Osteopath Assoc; 2003 Feb; 103(2 Suppl 2):S3-5. PubMed ID: 12625631
    [No Abstract]   [Full Text] [Related]  

  • 11. [Postmenopausal hormone replacement therapy and cardiovascular risk: role of conjugated equine estrogens and medroxyprogesterone acetate].
    Ortmann J; Traupe T; Vetter W; Barton M
    Praxis (Bern 1994); 2004 May; 93(21):904-14. PubMed ID: 15216975
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The effect of medroxyprogesterone acetate on estrogen-dependent risks and benefits--an attempt to interpret the Women's Health Initiative results.
    Kuhl H; Stevenson J
    Gynecol Endocrinol; 2006 Jun; 22(6):303-17. PubMed ID: 16785155
    [TBL] [Abstract][Full Text] [Related]  

  • 13. NIH workshop tries to create consensus on HRT use.
    Randal J
    J Natl Cancer Inst; 2003 Jan; 95(1):9-11. PubMed ID: 12509392
    [No Abstract]   [Full Text] [Related]  

  • 14. Use of combination hormone replacement therapy in light of recent data from the Women's Health Initiative.
    Kaunitz AM;
    Medscape Womens Health; 2002; 7(4):8. PubMed ID: 12466740
    [No Abstract]   [Full Text] [Related]  

  • 15. Women's health. The vanishing promises of hormone replacement.
    Enserink M
    Science; 2002 Jul; 297(5580):325-6. PubMed ID: 12130763
    [No Abstract]   [Full Text] [Related]  

  • 16. Re: Estrogen plus progestin therapy and breast cancer in recently postmenopausal women.
    Langer RD
    Am J Epidemiol; 2009 Mar; 169(6):784-5; author reply 785-6. PubMed ID: 19208722
    [No Abstract]   [Full Text] [Related]  

  • 17. Cognitive effects of estrogens in women with cardiac disease: what we do not know.
    Sano M; Bell K; Jacobs D
    Am J Med; 2002 Nov; 113(7):612-3. PubMed ID: 12459411
    [No Abstract]   [Full Text] [Related]  

  • 18. Estrogen research. Brain researchers try to salvage estrogen treatments.
    Wickelgren I
    Science; 2003 Nov; 302(5648):1138-9. PubMed ID: 14615509
    [No Abstract]   [Full Text] [Related]  

  • 19. Reduced vaginal bleeding in postmenopausal women who receive combined norethindrone acetate and low-dose ethinyl estradiol therapy versus combined conjugated equine estrogens and medroxyprogesterone acetate therapy.
    Simon JA; Liu JH; Speroff L; Shumel BS; Symons JP
    Am J Obstet Gynecol; 2003 Jan; 188(1):92-9. PubMed ID: 12548201
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Risks of estrogen plus progestin therapy: a sensitivity analysis of findings in the Women's Health Initiative randomized controlled trial.
    Shapiro S
    Climacteric; 2003 Dec; 6(4):302-10; discussion 310-3. PubMed ID: 15006251
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.